摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-4-(三氟甲氧基)苯甲酸 | 158580-93-9

中文名称
3-氯-4-(三氟甲氧基)苯甲酸
中文别名
3-氯-4-(三氟甲氧基)苯甲酸, 97+%;3-氯-4-三氟甲氧基苯甲酸
英文名称
3-chloro-4-(trifluoromethoxy)benzoic acid
英文别名
m-chloro-p-(trifluoromethoxy)benzoic acid;3-chloro-4-[(trifluoromethyl)oxy]benzoic acid;3-chloro-4-trifluoromethoxybenzoic acid
3-氯-4-(三氟甲氧基)苯甲酸化学式
CAS
158580-93-9
化学式
C8H4ClF3O3
mdl
——
分子量
240.566
InChiKey
QGVQWEOEEXGRSD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    258.9±35.0℃ (760 Torr)
  • 密度:
    1.558±0.06 g/cm3 (20 ºC 760 Torr)
  • 闪点:
    110.4±25.9℃

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    6

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2918990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:01a4eb3dab815fd1a6f26a98f5774050
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Chloro-4-(trifluoromethoxy)benzoic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-4-(trifluoromethoxy)benzoic acid
CAS number: 158580-93-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H4ClF3O3
Molecular weight: 240.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氯-4-(三氟甲氧基)苯甲酸 氢气1-羟基苯并三唑溶剂黄1461-(3-二甲基氨基丙基)-3-乙基碳二亚胺三乙胺 作用下, 以 甲醇N,N-二甲基甲酰胺 、 xylene 为溶剂, 反应 200.0h, 生成 2-(3-chloro-4-(trifluoromethoxy)phenyl)-5-(3,5-dichlorophenyl)-4,5-dihydro-1H-imidazole
    参考文献:
    名称:
    Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists
    摘要:
    A novel series of cyclic benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 29 is orally active in a carrageenan-induced rat hyperalgesia model of pain. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.04.084
  • 作为产物:
    描述:
    4-溴-2-氯-1-三氟甲氧基苯正丁基锂 作用下, 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 异丙醚 为溶剂, 生成 3-氯-4-(三氟甲氧基)苯甲酸
    参考文献:
    名称:
    4-benzoyl isoxazoles derivatives and their use as herbicides
    摘要:
    4-苯甲酰异噁唑衍生物的化学式如下: 其中,R为H或酯基;R1为烷基、卤代烷基或可选择取代的环烷基;R2为卤素、可选择卤代烷基、烯基或炔基;烷基上取代有一个或多个—OR5;—NO2、—CN、—CO2R5、—S(O)pR6、—O(CH2)mOR5、—COR5、—NR5R6、—N(R8)SOqR7、—CONR9R10或—OR51;或可选择取代的苯基;R3为—S(O)qR7;X为—N(R8)—;n为0、1、2、3或4;R5、R51和R6独立地为H;可选择卤代烷基、烯基或炔基;可选择取代的苯基;或环烷基;R7为可选择卤代烷基、烯基或炔基;环烷基;可选择取代的苯基;或可选择取代的氨基;R8为H;可选择卤代烷基、烯基或炔基;环烷基;可选择取代的苯基;或烷氧基;m为1、2或3;p为0、1或2;q为0或2;并描述了它们作为除草剂的用途。
    公开号:
    US06323155B1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS<br/>[FR] NOUVEAUX COMPOSES DE BENZAMIDE DESTINES A ETRE UTILISES DANS DES TROUBLES ASSOCIES AU RECEPTEUR DE MCH
    申请人:7TM PHARMA AS
    公开号:WO2004048319A1
    公开(公告)日:2004-06-10
    Novel compounds of Formula I which modulate MCH activity are disclosed, in which A is a linker, Ar, is an aryl or heteroaryl group; R1 is hydrogen or a lower alkoxy group; Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, -CHO, nitrile, alkyl, alkenyl or alkynyl groups, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, -CF2CF3, -CF3, -OCF3, -SCF3; -SO2NH2, -SO2NHAlk, -SO2NAlk2, -SO2AIk; R8 is hydrogen, halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylcycloalkyl groups, alkoxy groups, dialkylamino groups, -CONHAIk, -CONAIk2, - NHCO-Alk, -CO-Alk, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, -CF2CF3, -CF3, -OCF3, -SCF3; X is H, F, Cl, Br, I, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, - CF2CF3, -CF3, -OCF3, -SCF3; OCH3 or lower alkyl or alkenyl group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.
    公开了调节MCH活性的Formula I的新化合物,其中A是连接剂,Ar是芳基或杂环芳基;R1是氢或较低的烷氧基;Q与羰基一起形成酰胺基团,该基团进一步被氨基取代;R5是氢、卤素原子、烷氧基、羟基、烷基氨基基团、二烷基氨基基团、羟基烷基基团、羧酰胺基团、酰胺基团、酰基、-CHO、腈基、烷基、烯基或炔基、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团,如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3;-SO2NH2、-SO2NHAlk、-SO2NAlk2、-SO2AIk;R8是氢、卤素原子、烷基、烯基或炔基、环烷基、烷基环烷基、烷氧基、二烷基氨基基团、-CONHAIk、-CONAIk2、-NHCO-Alk、-CO-Alk、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团,如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3;X是H、F、Cl、Br、I、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团,如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3;OCH3或较低的烷基或烯基基团;这些化合物在治疗或预防肥胖、抑郁症、糖尿病、暴食症等方面是有用的。
  • [EN] NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS<br/>[FR] NOUVEAUX COMPOSES DE METHOXYBENZAMIDE DESTINES A ETRE UTILISES DANS LE TRAITEMENT DES TROUBLES LIES AU RECEPTEUR DE MCH
    申请人:7TM PHARMA AS
    公开号:WO2003087045A1
    公开(公告)日:2003-10-23
    Novel compounds of Formula (I) which modulate MCH activity are disclosed, in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH2 group, Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is selected from hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, -CHO, nitrile, alkyl, alkenyl or alkynyl groups, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, -CF2CF3, -CF3, -OCF3, -SCF3; -SO2NH2, -SO2NHAlk, -SO2NAlk2, -SO2Alk; X is H, F, Cl, Br, I, -SCH3, -CF3, -OCF3, -SCF3, OCH3, or lower alkyl or alkenyl group; R8 is halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, heterocyclyl groups, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, alkylheteroaryl groups, arylalkoxy groups, aryloxy groups, alkoxy groups, dialkylamino groups, -CONHAlk, -CONHAr, -CONAlk2, -NHCO-Alk, -NHCO-Ar, -CO-Alk, -CO-Ar, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups; or R8 is R6-Ar2-B-, in which B is a single bond or a connecting moiety; Ar2 is an Ar1 group; R6 is an R5 group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.
    化合物的新颖化合物的公式(I),其调节MCH活性,其中A是连接剂;Ar1是芳基或杂芳基;R1是较低的烷氧基团;R2是R1基团或氢,OH或NH2基团,Q与羰基一起形成酰胺基团,该基团进一步被氨基团取代;R5从氢,卤素原子,烷氧基团,羟基,烷基氨基团,二烷基氨基团,羟基烷基基团,羧酰胺基团,酰胺基团,酰基,-CHO,腈,烷基,烯基或炔基团,-SCH3,部分或完全氟化的烷基,烷氧基或硫代烷氧基团,如-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3;-SO2NH2,-SO2NHAlk,-SO2NAlk2,-SO2Alk;X是H,F,Cl,Br,I,-SCH3,-CF3,-OCF3,-SCF3,OCH3,或较低的烷基或烯基基团;R8是卤素原子,烷基,烯基或炔基团,环烷基团,芳基,杂芳基,杂环烷基团,烷基环烷基团,烷基芳基团,烷基杂环烷基团,烷基杂芳基团,芳基烷氧基团,芳氧基团,烷氧基团,二烷基氨基团,-CONHAlk,-CONHAr,-CONAlk2,-NHCO-Alk,-NHCO-Ar,-CO-Alk,-CO-Ar,-SCH3,部分或完全氟化的烷基,烷氧基或硫代烷氧基团;或R8是R6-Ar2-B-,其中B是单键或连接基;Ar2是Ar1基团;R6是R5基团;在治疗或预防肥胖,抑郁症,糖尿病,暴食症等方面是有用的。
  • Poly(methylhydrosiloxane) as a green reducing agent in organophosphorus-catalysed amide bond formation
    作者:Daan F. J. Hamstra、Danny C. Lenstra、Tjeu J. Koenders、Floris P. J. T. Rutjes、Jasmin Mecinović
    DOI:10.1039/c7ob01510k
    日期:——
    efficient organophosphorus-catalysed amidation reaction between unactivated carboxylic acids and amines. Poly(methylhydrosiloxane), a waste product of the silicon industry, is used as an inexpensive and green reducing agent for in situ reduction of phosphine oxide to phosphine. The reported method enables the synthesis of a wide range of secondary and tertiary amides in very good to excellent yields.
    在过去十年中,催化酰胺键形成反应的发展一直是深入研究的主题。本文中,我们报道了未活化的羧酸和胺之间有效的有机磷催化的酰胺化反应。聚(甲基氢硅氧烷)是硅工业的废品,被用作廉价和绿色的还原剂,用于将氧化膦原位还原为膦。所报道的方法能够以非常好的至优异的产率合成多种仲和叔酰胺。
  • [EN] AMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'AMIDE COMME BLOQUEURS DE TTX-S
    申请人:RAQUALIA PHARMA INC
    公开号:WO2013161308A1
    公开(公告)日:2013-10-31
    The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及酰胺衍生物,具有对电压门控钠通道(如TTX-S通道)的阻塞活性,可用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的疾病中使用这些化合物和组合物。
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    申请人:Takeda Pharmaceutical Company Limited
    公开号:US20190300536A1
    公开(公告)日:2019-10-03
    The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    本发明提供一种具有对包含NR2B亚基的NMDA受体具有拮抗作用的杂环化合物,预计可作为预防或治疗重度抑郁症、双相情感障碍、偏头痛、疼痛、痴呆症的行为和心理症状等的药物。本发明涉及一种由以下式(I)表示的化合物:其中每个符号如描述中所述,或其盐。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐